Bright Minds Biosciences ... (DRUG)
35.34
-1.90 (-5.10%)
At close: Mar 03, 2025, 3:59 PM
34.92
-1.18%
After-hours: Mar 03, 2025, 04:00 PM EST
Company Description
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases.
Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin.
The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Bright Minds Biosciences Inc.

Country | CA |
IPO Date | Mar 22, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | n/a |
CEO | Ian McDonald |
Contact Details
Address: 1500 – 1055 West Georgia Street Vancouver, BC CA | |
Website | https://brightmindsbio.com |
Stock Details
Ticker Symbol | DRUG |
Exchange | NASDAQ |
Fiscal Year | October - September |
Reporting Currency | USD |
CIK Code | 0001827401 |
CUSIP Number | 10919W108 |
ISIN Number | CA10919W4056 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Ian McDonald | Co-Founder, Chief Executive Officer, President & Director |
Alex Vasilkevich | Chief Operating Officer & Vice President of Corporate Development |
Ryan E. S. K. Cheung B.Com., CA, CPA | Chief Financial Officer |
Dr. Emer Leahy M.B.A., Ph.D. | Consultant |
Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Chief Science Officer & Director |
Dr. Stephen D. Collins M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 24, 2025 | 6-K | Filing |
Feb 14, 2025 | 424B3 | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | 6-K | Filing |
Feb 10, 2025 | SCHEDULE 13G | Filing |
Feb 07, 2025 | SCHEDULE 13G | Filing |
Feb 05, 2025 | F-3 | Filing |